Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis

Exclusion Criteria

• •1. Has severe claustrophobia or any medical condition that would prevent completion of the imaging protocol
• •2. Has a known allergy to potassium iodide treatment or to gadolinium.
• •3. Patients on dialysis or those with eGFR \<30 cc/min/1.73 m2 will be excluded from undergoing gadolinium-enhanced cardiac MRI.
• •4. Has received heparin or heparin analogs (e.g., enoxaparin, dalteparin, fondaparinux) within 7 days prior to 124I-Evuzumitide administration